429 results about "Metabolic pathway" patented technology

The invention relates to the technical field of genetic engineering, and particularly discloses a genetic engineering bacterium for producing melanin as well as a construction method and application of the genetic engineering bacterium. According to the application, the yield of the melanin can be effectively increased by modifying a metabolic pathway of the genetically engineered bacterium, and the yield of the melanin reaches 6.2 g / L and 18.5 g / L respectively through shake-flask culture and 5L fermentation tank culture. Compared with the prior art, the yield of melanin produced by the genetically engineered bacterium is improved by 30% at the shake flask fermentation level, the fermentation yield of a fermentation tank is improved by 4.3 times, in addition, expensive tyrosine is changed into glucose as a fermentation precursor substance, the production cost is greatly reduced, and an efficient and feasible solution is provided for large-scale production of melanin.

The invention provides a yak healthy feeding optimization method and system based on machine learning. The yak healthy feeding optimization method comprises the steps of obtaining a basic data set; according to the basic data set, performing erucic acid metabolic pathway feature construction to obtain a feature set representing erucic acid mediated lipid metabolic pathway; according to the lipid metabolism path feature set, meat quality improvement effect quantification is carried out, and probability distribution of unsaturated fatty acid deposition efficiency is obtained; according to the probability distribution, feeding amount reverse deduction is carried out, and a high-erucic-acid rapeseed oil intake interval is obtained through calculation; health benefit balance is carried out according to a high-erucic acid rapeseed oil intake interval, and a stable feeding strategy is obtained; biological rationality verification is carried out according to a stable feeding strategy, the continuity of the mapping relation between the feeding amount and the meat quality index is analyzed based on the topological structure of the feature space, and a healthy yak feeding optimization scheme is obtained. The feeding precision, the meat quality improvement effect stability and the yak health guarantee level are improved.

The invention relates to the technical field of plant breeding, and particularly discloses a metabonomics-based alfalfa stress resistance gene analysis function and a breeding method. The core of the method is that screening is carried out by combining a tissue culture technology with metabolic intervention; an alfalfa explant is inoculated into an induction culture medium containing a specific metabolic pathway regulator for metabolic intervention culture; then transferring the obtained callus to a verification culture medium containing the metabolism regulator and an abiotic adversity stress factor at the same time, and carrying out metabolism mark verification and screening; and finally regenerating the screened cell line into a complete plant. According to the method, metabolic pressure is actively applied to the cellular level, and dual verification screening is implemented, so that early-stage, efficient and accurate breeding of the stress-resistant alfalfa material is realized, and the technical problems of long period, low efficiency and insufficient utilization of metabolic information in traditional breeding are solved.

The invention discloses a risk assessment method, system and equipment for idiopathic pulmonary arterial hypertension, and belongs to the field of pulmonary arterial hypertension. According to the method, SNP data containing genotypes and effect values, protein marker expression quantity, metabonomics and clinical data are obtained, the SNP effect values are corrected based on linkage imbalance reference information, and PRS is calculated in combination with the genotypes; constructing a protein expression score by utilizing the site effect value and the expression quantity of the pQTL, and fusing the protein expression score with the PRS to form a target PRS; carrying out dimensionality reduction on metabolome data by adopting sparse coding, extracting sparse coefficients of IPAH related metabolic pathways, and converting the sparse coefficients into metabolic pathway scores; converting the clinical indexes into clinical risk scores; based on the clinical parameter distribution target PRS, the metabolic pathway score and the weight coefficient of the clinical risk score, calculating a risk assessment value; and finally, matching the evaluation value with a preset risk threshold value, and outputting a risk evaluation level. And the IPAH risk assessment accuracy of common people is improved.

The invention relates to a strong promoter P7 suitable for streptomyces and application thereof, and relates to the field of genetic engineering and microbial metabolism engineering. The nucleotide sequence of the strong promoter P7 is as shown in SEQ ID No.1, and the strong promoter comprises a plasmid vector of the strong promoter; a host cell comprising the plasmid vector; the invention also discloses application of the strong promoter, the plasmid vector and the host cell in starting expression of a target gene. Compared with the prior art, the characterization of the strong promoter P7 provides an effective tool element for streptomyces strong promoter engineering and high-efficiency gene expression, and has important significance on streptomyces silent gene characterization, high-efficiency gene expression, metabolite synthesis, metabolic pathway reconstruction and the like. The strong promoter can be applied to common streptomyces type strains, and has important significance on high yield of important proteins including enzymes and important metabolites from actinomycetes.

The present disclosure provides a recombinant Escherichia coli strain modified by metabolic engineering means and a method for producing L-homoserine by using the same. The strain, designated as Escherichia coli having a strain number of 13-XA, is deposited in China General Microbiological Culture Collection Center (CGMCC) with an accession number of CGMCC No. 25099, dated Jun. 16, 2022. With respect to the chromosome DNA thereof, one or more genes associated with fatty acid metabolism are knocked out or attenuated, and / or a promoter is replaced for enhancement; one or more genes associated with the L-homoserine metabolic pathway are knocked out or attenuated, and / or one or more genes associated with the L-homoserine metabolic pathway are overexpressed or enhanced, and / or one or more genes associated with the L-homoserine metabolic pathway are mutated.

The invention discloses a fermentation process for shortening a fermentation period and efficiently synthesizing Ectoine. The fermentation process comprises the following steps: screening and activating high-yield strains, preparing a fermentation culture medium, performing fermentation culture, performing sectional dissolved oxygen regulation and control, performing double-stage pH dynamic regulation and control, performing carbon-nitrogen ratio dynamic regulation based on metabolic flow analysis, performing osmotic pressure gradient induction in the later stage of fermentation, and extracting and purifying a product. According to the fermentation process for shortening the fermentation period and efficiently synthesizing the Ectoin, the expression quantity of key enzymes for synthesizing the Ectoin is increased by 80% or above compared with that of an original strain through the Halomonassp.ECT-09 strain bred through ultraviolet-nitrosoguanidine compound mutation, the basic yield reaches 35 g / L, a foundation is laid for high yield, and the method is suitable for industrial production. A glucose-trehalose mixed carbon source and a yeast extract-ammonium nitrate mixed nitrogen source are adopted, and an L-aspartic acid-L-asparagine mixed precursor is added, so that the metabolic pathway is shortened, and the loss of an intermediate product is reduced.

The invention discloses a salicylic acid decarboxylase mutant and application of the salicylic acid decarboxylase mutant in degradation of salicylic acid. The mutant is obtained by carrying out site-specific modification on salicylic acid decarboxylase NahG, and specifically, valine at the 46th site, tyrosine at the 380th site and leucine at the 382nd site of an amino acid sequence shown in SEQ ID NO.2 are mutated into cysteine, phenylalanine and phenylalanine at the same time. The mutant shows remarkably improved catalytic efficiency, and salicylic acid can be efficiently and thoroughly decarboxylated and converted into catechol under mild conditions. The invention also provides a coding gene, a recombinant vector and an engineering bacterium of the mutant. The mutant not only can be used for efficient bioremediation of salicylic acid pollution, but also can effectively break through and accelerate a naphthalene catabolism pathway due to the characteristic of directionally generating catechol, and has important application value in the fields of environmental pollution abatement and biological catalysis.

The invention discloses a method for analyzing component difference between Maotai-flavor yeast and yeast-making wheat by using non-targeted metabonomics. The method comprises the following steps: S1, pre-treating a sample; s2, detecting each sample by adopting the combination of an ultra-high performance liquid chromatograph and a quadrupole time-of-flight mass spectrometer; s3, acquiring original data, performing peak extraction, peak alignment and normalization by adopting metabonomics data analysis software, and evaluating the overall difference and intra-group variation among sample groups by adopting principal component analysis; constructing a grouping discrimination model through discriminant analysis of an orthogonal partial least square method; determining differential metabolites of the two groups of samples by taking variable projection importance (VIP) greater than 1 and statistical significance P less than 0.01 as a primary screening standard and combining a secondary screening standard that the difference multiple log2FC greater than 2 is up-regulated and the difference multiple log2FC less than-2 is down-regulated; s4, performing compound structure and category annotation on the screened differential metabolites through a metabolome database; and performing pathway enrichment analysis by adopting a statistical test method, and determining a core metabolic pathway enriched by the differential metabolites.

The invention provides application of a roxburgh rose extract in preparation of a product for treating hyperuricemia and regulation and control of a purine metabolic pathway, and belongs to the technical field of biological medicines. The roxburgh rose aqueous extract extracted from roxburgh rose pomace can effectively intervene in hyperuricemia through a dual action mechanism: on one hand, the roxburgh rose aqueous extract significantly inhibits the expression of xanthine oxidase (XOD) in the liver, and reduces the generation of uric acid; on the other hand, expression of key urate transporters (including GLUT9, URAT1, ABCG2 and OAT1) is regulated and controlled, uric acid is promoted to be excreted through the kidney, and therefore the blood uric acid level is reduced in a synergistic mode, a solid theoretical basis and technical support are provided for developing a new HUA prevention and treatment strategy based on natural products, and a new thought is provided for prevention and treatment of hyperuricemia.

The invention discloses a liquid-state stable system and application thereof, a solute in the liquid-state stable system comprises one or more of homocysteine metabolic pathway compounds, a stabilizer contains DTT and ascorbic acid and / or erythorbic acid, and a solvent is a methanol aqueous solution. The stabilizer disclosed by the invention is simple in component, can play a role in stabilizing homocysteine metabolic pathway compounds at the same time, particularly can play a very good role in stabilizing homocysteine metabolic pathway compounds with different stabilizer requirements at the same time, and effectively and greatly reduces the degradation rate of each compound. When the liquid stable system is applied to preparation of a homocysteine metabolic pathway compound detection kit, the liquid stable system can be used as a calibration product, a quality control product, an internal standard working solution and other components, has good stability, is beneficial to prolonging the shelf life of a kit product and reducing the storage cost, and is suitable for industrial production. When the kit is used for quantitative detection of homocysteine metabolic pathway compounds, the detection result is more reliable, and more valuable data support is provided for research and application in related fields.

The invention relates to the technical field of medical assistance, in particular to a depression risk assessment method and system based on intestinal flora characteristics. The method comprises the following steps: acquiring an individual enteric microorganism sample, performing nucleic acid sequencing on the enteric microorganism sample, and determining abundance data of functional genes related to a neural activity metabolic pathway in enteric microorganisms; carrying out metabolite detection on the intestinal microorganism sample, and determining concentration data of metabolites related to the neural activity metabolic pathway in the intestinal microorganisms; based on the abundance data of the functional genes and the concentration data of the metabolites, data fusion processing is carried out, a neural activity metabolism function spectrum is constructed, and the neural activity metabolism function spectrum is a multi-dimensional feature vector; and inputting the neural activity metabolic function spectrum into a pre-trained risk assessment model, and outputting a depression risk score of the individual. The accuracy and repeatability of evaluation are remarkably improved, and the method has great potential for early screening, dynamic monitoring and personalized health management.

The invention belongs to the technical field of plant genetic engineering, and particularly relates to an application of SlERF098 protein and a coding gene thereof in regulating and controlling steroid alkaloid content to influence botrytis cinerea resistance. According to the application, the resistance of tomatoes to gray mold is enhanced by regulating and controlling the metabolism of steroid glycoalkaloid through the coding gene. The tomato SlERF098 gene is positioned through whole genome association analysis, and an overexpression strain and an RNA interference strain of the tomato SlERF098 gene are constructed. Experiments prove that the SlERF098 can obviously activate the expression of the GAMEs gene in the SGAs metabolic pathway. In addition, overexpression of the SlERF098 gene can improve the content of SGAs metabolites in tomatoes and the resistance to gray mold, while RNA interference strains present an opposite trend. The invention provides a new target for research on disease-resistant molecular breeding and plant immunity-metabolism coordinated regulation and control, and has important agricultural application value.

The invention discloses a newborn inherited metabolic disease risk assessment method based on multi-modal collaborative learning, and the method comprises the following steps: collecting and preprocessing gene, metabolism and phenotype data, and constructing normalized multi-modal input features; constructing a cross-modal interaction network, and extracting fusion features from the preprocessed data to enhance the expression ability of pathological information; constructing a metabolic pathway diagram, and modeling a structure and function relationship between metabolites by using a diagram convolutional network; and performing feature alignment on the multi-modal features and a metabolic pathway diagram representation vector, and realizing efficient multi-modal fusion reasoning based on a confidence-guided incremental attention mechanism to complete disease data processing. Through multi-modal data fusion and graph convolutional network modeling, the pathological information expression ability is enhanced, efficient fusion reasoning is realized, and the accuracy and efficiency of neonatal disease data processing are improved.

Provided herein is a non-naturally occurring microbial organism having a methanol metabolic pathway (MMP) that can enhance the availability of reducing equivalents in the presence of methanol. Such reducing equivalents can be used to increase the product yield of organic compounds produced by the microbial organism, such as 1,4-butanediol (BDO). Also provided herein are methods for using such an organism to produce BDO.

The invention relates to the technical field of biology, in particular to a phloretin-O-monoglucoside glycosyl transferase protein DoUGT019 in dendrobium officinale as well as an encoding gene and application thereof, and discloses a phloretin-O-monoglucoside glycosyl transferase protein with an amino acid sequence as shown in SEQ ID NO: 1, which can be used for preparing a glycosyl transferase protein with an amino acid sequence as shown in SEQ ID NO: 1 in the presence of a UDP-glucose donor. The method has the advantages that the method is simple and convenient to operate and can catalyze O-glycosylation of phloretin A ring 2 '-OH, 4'-OH and B ring 4-OH, three high-value monoglucosides, namely phlorizin, trilobatin and phloretin-4-O-glucoside, are synchronously generated, multi-product synthesis can be realized without synergy of various enzymes, the process is greatly simplified, and the use cost of enzyme preparations is reduced. Meanwhile, discovery of the protein reveals a unique phloretin glycosylation metabolic pathway of dendrobium plants, and a cloning and functional verification system of the protein can also be used as a general technical template for research of similar glycosyltransferase to promote technical iteration and theoretical development in the field of glycosylation biosynthesis.

The invention belongs to the technical field of bioengineering and microbiomics, and particularly relates to an acquisition method and application of a specific metabolic substrate of lactobacillus crispatus and application of a specific carbohydrate active enzyme CAZzyme gene and a polysaccharide utilization site (PUL). Genomes of lactobacillus crispatus and lactobacillus inertus are obtained from a public database, gene annotation is carried out on the genomes of the lactobacillus crispatus and the lactobacillus inertus, and a random forest model and a KEGG metabolic pathway diagram are combined to find specific CAZzyme genes, PUL and other genes with metabolic functions of the lactobacillus crispatus; a substrate which only lactobacillus crispatus can metabolize is searched based on the genome difference of the two bacteria, and the ability of the obtained substrate for promoting the growth of lactobacillus crispatus and inhibiting the growth of inert lactobacillus is evaluated through experiments. Growth and reproduction of the lactobacillus crispatus are promoted through the substrates, so that the lactobacillus crispatus accounts for a higher proportion in vagina microecology, the vagina is protected, and reproduction of other unfavorable bacteria is reduced. The assisted reproduction success rate is improved.

This invention discloses a method for preparing spiramycin EP impurity G, comprising the following steps: (1) adding spiramycin I to a solvent, adding alkali and esterification reagent, and selectively esterifying at 10-30℃ to obtain a compound; (2) adding the compound to a solvent, adding alkali and esterification reagent, and selectively esterifying to obtain a compound; (3) adding the compound to an acidic solvent with pH 0.8-2.0, and selectively hydrolyzing at 0-40℃ to obtain a compound; (4) adding the compound to a solvent, adding alkali, and selectively hydrolyzing to obtain spiramycin EP impurity G. This invention uses spiramycin I as a starting point and obtains spiramycin EP impurity G through selective esterification, esterification, and two-step selective hydrolysis. The product purity can reach over 94%, which is helpful for studying the metabolic pathways and processes of spiramycin and clarifying the absorption, distribution, metabolism, and excretion characteristics of the drug.

The present application relates to the field of microorganism, and particularly to a strain of Buttiauxella agrestis 33, a vegetable fresh-keeping agent and application thereof.The present application provides a strain of Buttiauxella agrestis 33, and the preservation number of the strain is CGMCC No.34251.After the strain is used to treat green flower, the yellowing of the green flower after harvesting can be significantly inhibited.Then, the expression of genes related to chlorophyll metabolic pathway and antioxidant enzyme in the green flower treated by the Buttiauxella agrestis 33 is detected by real-time fluorescent quantitative reverse transcription PCR, and the result shows that the Buttiauxella agrestis 33 can inhibit the yellowing of the green flower after harvesting and improve the antioxidant capacity of the green flower by activating the expression of genes related to chlorophyll synthesis and antioxidant enzyme.

Affinity-based and activity-based probes (ABPs) described herein offer transformative resolutions to microbiome function. These ABPs target key metabolic pathways in the gut microbiome. The ABPs contain a binding group, a reactive group, and a. reporter group handle that allows for the addition of a "flexible" reporter group that can be easily swapped to enable multimodal fluorescence and proteomic measurements and isolation of live cells. The binding group, also called an affinity element or biorecognition element, mirrors monomeric and polymeric carbohydrates, sulfated and acetylated carbohydrates, and peptides to afford probe selectivity.

The invention discloses a method for improving yield of branched chain aldehyde of lactococcus lactis based on regulation and control of a luxS gene and application, and belongs to the field of system biology. Gene function verification and genome scale metabolic network model analysis are creatively combined, the phenotypic effect of the luxS gene is confirmed, and more importantly, the internal action mechanism of the luxS gene is disclosed from the system level, that is, the whole metabolic network flow is influenced by regulating and controlling multiple key enzymes such as transaminase, decarboxylase, dehydrogenase and decarboxylase. The invention reveals that the quorum sensing core gene luxS has a new function of regulating and controlling synthesis of branched chain aldehyde in lactococcus lactis for the first time, and an intercellular communication system is directly linked with production of specific flavor metabolites. The invention provides a brand-new and higher-level regulation target and thought for producing flavor substances by microbial fermentation, and gets rid of the limitation that only metabolic pathway terminal enzyme is singly modified traditionally.

This invention relates to the field of nutritional food technology, specifically to a fat-reducing composition for regulating the gut and its preparation method. The fat-reducing composition for regulating the gut comprises the following components by weight percentage: 20-25% solid coconut diglyceride microcrystalline powder, 15-20% fermented gel freeze-dried powder, 3-5% citrus pectin, 8-12% psyllium husk powder, 10-15% defatted coconut powder, 5-8% resistant dextrin, 8-10% pea protein powder, 3-5% freeze-dried mango powder, 4-7% erythritol, 1-2% microcrystalline cellulose, and 0.5-1% citric acid powder. This invention effectively solves the core problems of traditional fat-reducing products—poor ingredient stability, low bioavailability, and limited efficacy—through the dual progressive effects of physical structure and biological fermentation. It systematically achieves a synergistic effect of delaying fat digestion and absorption, long-lasting satiety enhancement, and precise regulation of gut microbiota health, completing a systematic engineering leap from single-component stimulation to simulating human metabolic pathways. This provides a stable, efficient, and safe complete solution for fat-reducing functional foods that regulate the gut.

This invention provides a chalcone isopentenyltransferase gene. GiPT16 This invention relates to the GiPT16 protein, amplification primer set, and applications, belonging to the field of biogenetics technology. It is based on *Glycyrrhiza inflata* (GiPT16 protein, amplification primer set, and applications). Glycyrrhiza inflata Using whole-genome sequencing data and a reverse genetics strategy, the key aromatic isopentenyltransferase GiPT16, involved in the isopentenylation modification of chalcone active ingredients, was successfully identified and functionally characterized. This enzyme was confirmed to specifically catalyze the biosynthesis of psoralen and glycyrrhizin C using DMAPP as a donor. It is the first chalcone isopentenyltransferase characterized in *Glycyrrhiza inflata*, filling a gap in the study of key enzymes in the chalcone isopentenylation metabolic pathway of this species and providing important evidence for further elucidating the molecular mechanisms of quality formation in *Glycyrrhiza inflata* medicinal materials.

The invention provides a composition containing bile acid and bifidobacterium animalis subsp. Lactis for improving tear stains of dogs and cats. The composition is prepared from the bile acid and the bifidobacterium animalis subsp. Lactis ZYhyy-017, and the composition is prepared from the bile acid, the bifidobacterium animalis subsp. Lactis ZYhyy-017, the bifidobacterium animalis subsp. Lactis ZYhyy-017 and the bifidobacterium animalis subsp. Lactis ZYhyy-017. The bifidobacterium animalis subsp. Lactis ZYhyy-017 is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC No.37292, and the preservation date is January 6, 2026. The bifidobacterium animalis subsp. Lactis ZYhyy-017 is preserved in the China General Microbiological Culture Collection Center (CGMCC). The bile acid is chenodeoxycholic acid (CDCA). The composition regulates and controls a bile acid-porphyrin metabolic pathway in a targeted manner through the synergistic effect of bile acid and bifidobacterium animalis subsp. Lactis ZYhyy-017, porphyrin metabolism in pets is regulated from the source, intestinal and liver axis metabolism and liver functions are optimized, long-acting and safe improvement of tear stains of dogs and cats is achieved, and the composition has a wide application prospect. Meanwhile, the technical blank that bile acid and specific probiotics are synergistically applied to the field of tear stain improvement of dogs and cats is filled up, and the actual requirement for tear stain root improvement in pet feeding is met.

This invention discloses a *Trichoderma parareesei* strain for synthesizing ergothioneine and its applications, belonging to the fields of genetic engineering and bioengineering technology. This invention achieves heterologous ergothioneine synthesis by expressing *TrEGT1* and *TrEGT2* derived from *Trichoderma parareesei* in *Trichoderma parareesei*. By screening different promoters driving *TrEGT1* and *TrEGT2*, the optimal ergothioneine synthesis gene combination was obtained. Further, multiple copies of the gene combination were integrated, and the synthesis of precursor histidine was enhanced to improve the ergothioneine synthesis capacity of *Trichoderma parareesei*, achieving a shake-flask fermentation yield of 1200±12.3 mg / L and a 5L fermentation tank yield of 8.6 g / L. This invention integrates a heterologous metabolic pathway into *Trichoderma parareesei*, achieving high-efficiency ergothioneine production and facilitating low-cost, large-scale production of ergothioneine and its products.

The invention belongs to the field of food processing and fermentation engineering, and discloses a multi-strain composite leavening agent with multiple application characteristics and application of the multi-strain composite leavening agent in preparation of fermented milk. The fermentation agent is prepared from lactobacillus bulgaricus IMAU20428, lactobacillus bulgaricus IMAU20427, streptococcus thermophilus IMAU20229 and streptococcus thermophilus IMAU10630. Systematic research finds that different compounding proportions can significantly influence the fermentation time, post-acidification phenomenon, viscosity, water-holding capacity, texture characteristics, amino acid and organic acid content and metabolic pathway enrichment characteristics of the fermented milk. The composite leavening agent provided by the invention can realize differentiated development of fermented milk products through proportion regulation and control, and provides technical support for innovation of the dairy product industry.

The invention discloses a medicine lotus cell suspension factory system and method for directionally producing high-activity components based on a healthy target spot, and the system is characterized in that a health-oriented cell line design module, an intelligent scale culture module, a precise metabolism induction module and a targeted separation and product development module are in closed-loop linkage; and an innovative mode of reversely designing a production process from health requirements is realized. According to the method, aiming at specific targets of epidemic resistance, depression resistance, reproductive health and the like, a high-yield cell line is created through multi-omics analysis screening or gene editing, and large-scale culture is performed in an optimally controlled bioreactor; and the elicitor is utilized to accurately stimulate a metabolic pathway to directionally enrich high-value components such as liensinine, nuciferine, epigallocatechin gallate and the like. And finally, preparing a standardized extract by adopting a green extraction technology (such as ultrasonic extraction and supercritical CO2 extraction), wherein the standardized extract is used for functional foods, dietary supplements or medical products.

The invention discloses a black fungus AMY protein and a coding gene and application thereof, and belongs to the technical field of protein engineering. The invention provides a black fungus AMY protein as well as an encoding gene and application thereof in order to excavate a key enzyme gene of a starch sucrose metabolic pathway in black fungus, and discovers and verifies that the black fungus AMY protein and the encoding gene thereof play a key regulation and control role in inducing synthesis of black fungus alpha-amylase through transcriptome sequencing. A solid foundation is laid for deeply exploring the function of a key gene of a starch sucrose metabolic pathway.

The invention discloses a microbial community-based industrial wastewater toxicity rapid assessment method, and particularly relates to the technical field of toxicity assessment, and the method comprises the steps of S1, stress assessment platform construction, S2, stress response data acquisition, S3, community function redundancy quantification, S4, metabolic flux disturbance tracking, and S5, dynamic network toxicity index generation. The dynamic stress reactor is used for simulating the gradient change of the concentration of the wastewater, the evaluation accuracy of the fluctuation toxicity of the industrial wastewater is remarkably improved, the method is particularly suitable for industries with frequent impact loads such as pharmacy and petrochemical engineering, and the evaluation accuracy of the fluctuation toxicity of the industrial wastewater is remarkably improved by combining functional redundancy loss index and gene-enzyme activity decoupling coefficient double-level analysis. According to the method, toxicity targeting disturbance of a specific metabolic pathway is accurately recognized, the problem of leak detection of a traditional method on composite pollutants and high-redundancy communities is solved, dynamic environment parameters such as a dissolved oxygen variable coefficient and a pH recovery slope are fused to construct a multi-parameter toxicity index, the sensitivity to non-lethal recessive toxic substances is greatly enhanced, and the false negative risk is avoided.

The invention discloses a method and a system for analyzing immune cell change of an HER2 variant lung cancer patient. The method comprises the following steps: collecting a peripheral blood sample and carrying out single-cell RNA (Ribonucleic Acid) sequencing; performing quality control, standardization processing, dimensionality reduction and clustering analysis on the sequencing data; carrying out immune cell subset annotation on the clustering result based on a preset immune cell marker; analyzing cell communication modes among different immune cell subpopulations by using a ligand-receptor database; performing quantitative statistics on the proportion of various immune cells based on sample grouping; and further performing subpopulation fine analysis, quasi-time sequence trajectory reconstruction and metabolic pathway activity evaluation on the CD8 + T cells to construct a comprehensive immune cell map. According to the method, the multi-dimensional characteristics of the peripheral blood immune cells can be presented at high resolution, and the comprehensive analysis of the functional state, the communication network and the metabolic activity of the immune cells is realized. According to the system and the device, automatic operation and visual display of the method can be realized. According to the invention, the immune monitoring efficiency can be improved, and an effective tool is provided for immune treatment effect evaluation and disease mechanism research.